Stable cell line development is critical for biologics manufacturing, requiring integration methods that deliver high productivity, genomic stability, and regulatory compliance. This white paper from Abzena explores the advantages and trade-offs of random integration and semi-targeted integration strategies in CHO cell systems. It examines transcription efficiency, clonal stability, scalability, and regulatory considerations while highlighting how Abzena’s AbZelectPRO™ platform with 2G UNic® vector technology accelerates development and supports robust manufacturing outcomes.
Download the white paper here to read more.
